Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

This study has been terminated.
Sponsor:
Collaborators:
Cancer International Research Group
Hoffmann-La Roche
Genentech, Inc.
Information provided by (Responsible Party):
NSABP Foundation Inc
ClinicalTrials.gov Identifier:
NCT00625898
First received: February 21, 2008
Last updated: July 7, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2014
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)